R&D channel feed – Endpoints News

R&D channel feed

Heron's pain drug nails PhIII, prepping the company for NDA later this year

8 years ago

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

8 years ago

Adaptimmune shares boosted by new signs of success with TCR cell therapy

8 years ago

J&J's blockbuster hopeful erdafitinib gets 'breakthrough' moniker

8 years ago

Eli Lilly gets a date with FDA experts for once-rejected rheumatoid arthritis drug baricitinib

8 years ago

Alexion's successor to Soliris hits co-primary endpoints in a pivotal, but can't surpass the big blockbuster

8 years ago

Tracking a successful DLBCL assault in Phase II, MorphoSys sets out to seize quick OK for MOR208

8 years ago

Lousy year for shareholders, but Allergan CEO Brent Saunders sprints past Gorsky, Gonzalez with $32M pay package

8 years ago

0-for-3 in PhIII: Auris’ late-stage changeup fails to save tinnitus drug from another disaster

8 years ago

With rival to anti-TNF injectables, Protalix reports positive PhII data in ulcerative colitis

8 years ago

AbbVie sweeps back-to-back PhIIIs for uterine fibroid patients, adding to elagolix's blockbuster rep

8 years ago

Halted in US by FDA hold, Bellicum buoyed by some positive numbers from its European T cell study for pediatric AML

8 years ago

Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca -- biotech's shares plunge

8 years ago

Busy Sanofi takes a pass on one of Alnylam’s rare disease drugs, FDA offers ‘breakthrough’ status for PhIII

8 years ago

Sarepta plays nice with the FDA, sets out plans for second accelerated Duchenne pitch by year's end

8 years ago

With debt looming, browbeaten diet pill maker Orexigen goes bankrupt -- shares slide

8 years ago

Praluent Odyssey: Regeneron/Sanofi gun for market breakout with first-ever mortality benefit — and a big price discount

8 years ago

Voyager's gene therapy for Parkinson's shows promise in early data from small Phase Ib trial

8 years ago

In wake of Eli Lilly setback, Merck KGaA's leading BTK drug for autoimmune disease clears PhIIb hurdle

8 years ago

MyoKardia steps closer to the launch of a groundbreaking heart trial after finding its low-dose starting point

8 years ago

Failure in pivotal PhIII brain cancer trial drags Israel's VBL Therapeutics down

8 years ago

Sanofi is jettisoning its infectious disease unit to Evotec — handing over cash, staff and a pipeline

8 years ago

The underdog champion of Roche’s huge pRED group is out. John Reed is coming home to America

8 years ago

Novartis joins forces with LA tech company Science 37 to launch virtual clinical trials

8 years ago

First page Previous page 278 279 280281282 283 284 Next page Last page